Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel | Zendy

Adrian Koh | Zendy; Paolo Lanzetta | Zendy; Won Ki Lee | Zendy; ChiChun Lai | Zendy; Wai-Man Chan | Zendy; ChungMay Yang | Zendy; Chui Ming Gemmy Cheung | Zendy

Open Access

Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel

Author(s) -

Adrian Koh,

Paolo Lanzetta,

Won Ki Lee,

ChiChun Lai,

Wai-Man Chan,

ChungMay Yang,

Chui Ming Gemmy Cheung

Publication year - 2017

Publication title -

asia-pacific journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.163

H-Index - 20

ISSN - 2162-0989

DOI - 10.22608/apo.2016125

Subject(s) - aflibercept , macular degeneration , medicine , regimen , disease , blindness , bevacizumab , intensive care medicine , optometry , ophthalmology , surgery , chemotherapy

To summarize recommendations for the use of intravitreal aflibercept with a treat-and-extend regimen to manage neovascular age-related macular degeneration (nAMD) in the Asia-Pacific region. Although anti-vascular endothelial growth factor therapies have improved the quality of life of patients with nAMD, a leading cause of blindness and visual impairment, the high treatment frequency recommended by current guidelines places a significant burden on patients and healthcare providers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research